25 , 26 , 27 In the present study, we did not observe significant better response rates in patients with irAEs ( n = 17), although we saw a slight trend of a better mOS and mPFS in this subgroup of patients.
← all excerpts
Efficacy, safety and differential outcomes of immune-chemotherapy with gemcitabine, cisplatin and durvalumab in patients with biliary tract cancers: A multicenter real world cohort.
1
—
—